S3-Guideline “Exocrine Pancreatic Carcinoma” 20071 ... - DGVS

482
Leitlinie
261 Beger HG, Link KH, Gansauge F. Adjuvant regional chemotherapy in
advanced pancreatic cancer: results of a prospective study. Hepatogastroenterology
1998; 45: 638–643
262 Ghaneh P, Neoptolemos JP. Conclusions from the European Study
Group for Pancreatic Cancer adjuvant trial of chemoradiotherapy
and chemotherapy for pancreatic cancer. Surg Oncol Clin N Am
2004; 13: 567–587, vii-viii
263 Lohr M, Hoffmeyer A, Kroger J et al. Microencapsulated cell-mediated
treatment of inoperable pancreatic carcinoma. Lancet 2001; 357:
1591–1592
264 Mercadante S. Pain treatment and outcomes for patients with advanced
cancer who receive follow-up care at home. Cancer 1999;
85: 1849–1858
265 Zech DF, Grond S, Lynch J et al. Validation of World Health Organization
Guidelines for cancer pain relief: a 10-year prospective study.
Pain 1995; 63: 65–76
266 Marinangeli F, Ciccozzi A, Leonardis M et al. Use of strong opioids in
advanced cancer pain: a randomized trial. J Pain Symptom Manage
2004; 27: 409–416
267 Grahm AL, Andren-Sandberg A. Prospective evaluation of pain in exocrine
pancreatic cancer. Digestion 1997; 58: 542–549
268 Caraceni A, Portenoy RK. Pain management in patients with pancreatic
carcinoma. Cancer 1996; 78: 639–653
269 Ross GJ, Kessler HB, Clair MR et al. Sonographically guided paracentesis
for palliation of symptomatic malignant ascites. Am J Roentgenol
1989; 153: 1309–1311
270 McNicol E, Strassels S, Goudas L et al. Nonsteroidal anti-inflammatory
drugs, alone or combined with opioids, for cancer pain: a systematic
review. J Clin Oncol 2004; 22: 1975–1992
271 Carr DB, Goudas LC, Balk EM et al. Evidence report on the treatment of
pain in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 23–31
272 Payne R, Mathias SD, Pasta DJ et al. Quality of life and cancer pain:
satisfaction and side effects with transdermal fentanyl versus oral
morphine. J Clin Oncol 1998; 16: 1588–1593
273 De Conno F, Ripamonti C, Saita L et al. Role of rectal route in treating
cancer pain: a randomized crossover clinical trial of oral versus rectal
morphine administration in opioid-naive cancer patients with
pain. J Clin Oncol 1995; 13: 1004–1008
274 Cherny NI. The management of cancer pain. CA Cancer J Clin 2000;
50: 70–116; quiz 117 – 120
275 Gilmer-Hill HS, Boggan JE, Smith KA et al. Intrathecal morphine delivered
via subcutaneous pump for intractable pain in pancreatic cancer.
Surg Neurol 1999; 51: 6–11
276 Staats PS, Hekmat H, Sauter P et al. The effects of alcohol celiac plexus
block, pain, and mood on longevity in patients with unresectable
pancreatic cancer: a double-blind, randomized, placebo-controlled
study. Pain Med 2001; 2: 28–34
277 Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for
treatment of cancer pain: a meta-analysis. Anesth Analg 1995; 80:
290–295
278 Wong GY, Schroeder DR, Carns PE et al. Effect of neurolytic celiac
plexus block on pain relief, quality of life, and survival in patients
with unresectable pancreatic cancer: a randomized controlled trial.
Jama 2004; 291: 1092–1099
279 Stefaniak T, Basinski A, Vingerhoets A et al. A comparison of two invasive
techniques in the management of intractable pain due to inoperable
pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic
splanchnicectomy. Eur J Surg Oncol 2005; 31: 768–
773
280 Arends J, Bodoky G, Bozzetti F et al. ESPEN Guidelines on Enteral Nutrition:
Non-surgical oncology. Clin Nutr 2006; 25: 245–259
Adler G et al. S3-Guideline “Exocrine Pancreatic… Z Gastroenterol 2008; 46: 449–482
281 Arends J, Zuercher G, Fietkau R et al. DGEM Leitlinie Enterale Ernährung:
Onkologie. Akt Ernähr Med 2003; 28: 61–68
282 Bjelakovic G, Nikolova D, Gluud LL et al. Mortality in randomized
trials of antioxidant supplements for primary and secondary prevention:
systematic review and meta-analysis. Jama 2007; 297: 842–
857
283 Wigmore SJ, Falconer JS, Plester CE et al. Ibuprofen reduces energy expenditure
and acute-phase protein production compared with placebo
in pancreatic cancer patients. Br J Cancer 1995; 72: 185–188
284 Gordon JN, Trebble TM, Ellis RD et al. Thalidomide in the treatment of
cancer cachexia: a randomised placebo controlled trial. Gut 2005;
54: 540–545
285 Jatoi A, Windschitl HE, Loprinzi CL et al. Dronabinol versus megestrol
acetate versus combination therapy for cancer-associated anorexia:
a North Central Cancer Treatment Group study. J Clin Oncol 2002;
20: 567–573
286 Loprinzi CL, Kugler JW, Sloan JA et al. Randomized comparison of megestrol
acetate versus dexamethasone versus fluoxymesterone for
the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17:
3299–3306
287 Moss AC, Morris E, Mac Mathuna P. Palliative biliary stents for obstructing
pancreatic carcinoma. Cochrane Database Syst Rev
CD 004200 2006
288 Hausegger KA, Thurnher S, Bodendorfer G et al. Treatment of malignant
biliary obstruction with polyurethane-covered Wallstents. Am
J Roentgenol 1998; 170: 403–408
289 Isayama H, Komatsu Y, Tsujino T et al. A prospective randomised
study of “covered” versus “uncovered” diamond stents for the management
of distal malignant biliary obstruction. Gut 2004; 53: 729–
734
290 Speer AG, Cotton PB, Russell RC et al. Randomised trial of endoscopic
versus percutaneous stent insertion in malignant obstructive jaundice.
Lancet 1987; 2: 57–62
291 Urbach DR, Bell CM, Swanstrom LL et al. Cohort study of surgical bypass
to the gallbladder or bile duct for the palliation of jaundice due
to pancreatic cancer. Ann Surg 2003; 237: 86–93
292 DiFronzo LA, Egrari S, O’Connell TX. Choledochoduodenostomy for
palliation in unresectable pancreatic cancer. Arch Surg 1998; 133:
820–825
293 Aranha GV, Prinz RA, Greenlee HB. Biliary enteric bypass for benign
and malignant disease. Am Surg 1987; 53: 403–406
294 Song HY, Shin JH, Yoon CJ et al. A dual expandable nitinol stent: experience
in 102 patients with malignant gastroduodenal strictures.
J Vasc Interv Radiol 2004; 15: 1443–1449
295 Kaw M, Singh S, Gagneja H et al. Role of self-expandable metal stents
in the palliation of malignant duodenal obstruction. Surg Endosc
2003; 17: 646–650
296 Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations
for the use of white blood cell growth factors: an evidence-based
clinical practice guideline. J Clin Oncol 2006; 24:
3187–3205
297 Rizzo JD, Lichtin AE, Woolf SH et al. Use of epoetin in patients with
cancer: evidence-based clinical practice guidelines of the American
Society of Clinical Oncology and the American Society of Hematology.
J Clin Oncol 2002; 20: 4083–4107
298 Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use
of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Eur J Cancer 2007; 43: 258–270
299 Schuchter LM, Hensley ML, Meropol NJ et al. 2002 update of recommendations
for the use of chemotherapy and radiotherapy protectants:
clinical practice guidelines of the American Society of Clinical
Oncology. J Clin Oncol 2002; 20: 2895–2903
Downloaded by: Thieme Verlagsgruppe. Copyrighted material.